CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

Alcon Research

ALC
$31.90BLarge Cap

Next catalyst

Phase 3January 2027

Apraclonidine Ophthalmic Solution, Unit Dose Preservative Free

Ocular Hyperemia

Source

Get an email about ALC's next catalysts

Track Alcon Research (ALC) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.

Plus 4 more upcoming events in our data (earnings, Phase 3 readout, Phase 2 readout).See the timeline

Catalyst Timeline

5 upcoming, 1 past

Earnings

ALC Earnings Report

Nov 10, 2026

EPS Est: $0.89 | FQ end Sep/2026 | Call: amc

Phase 3Next

Apraclonidine Ophthalmic Solution, Unit Dose Preservative Free Phase 3 Est. Readout

January 2027~Apraclonidine Ophthalmic Solution, Unit Dose Preservative Free178

Estimated primary completion for Apraclonidine Ophthalmic Solution, Unit Dose Preservative Free trial (NCT07578363) in Ocular Hyperemia. Topline data typically follows completion by weeks to months.

Source
Phase 3

Apraclonidine Ophthalmic Solution, Unit Dose Preservative Free Phase 3 Est. Readout

February 2027~Apraclonidine Ophthalmic Solution, Unit Dose Preservative Free230

Estimated primary completion for Apraclonidine Ophthalmic Solution, Unit Dose Preservative Free trial (NCT07531043) in Ocular Hyperemia. Topline data typically follows completion by weeks to months.

Source
Phase 2

AR-14034 SR implant Phase 2 Est. Readout (NOVA-1)

April 2027~AR-14034 SR implant139

Estimated primary completion for AR-14034 SR implant trial (NCT05769153) in Neovascular Age-related Macular Degeneration (nAMD). Topline data typically follows completion by weeks to months.

Source
Phase 2

AR-14034 SR implant lower dose Phase 2 Est. Readout

April 2027~AR-14034 SR implant lower dose139

Primary completion for AR-14034 SR implant lower dose trial (NCT05769153) in Neovascular Age-related Macular Degeneration (nAMD)

Source

Market Overview

Stock performance and key metrics

NASDAQOphthalmic GoodsOphthalmology🇺🇸EuropeFORT WORTH25.6K employees

Alcon Inc. (German: Alcon AG) is a Swiss-American pharmaceutical and medical device company specializing in eye care products. Alcon is incorporated in the Canton of Fribourg, Switzerland, and its global headquarters are located in Geneva, but its main operational base is in Fort Worth, Texas, United States, where it employs about 4,500 people.

Website
Drug Pipeline

Moxifloxacin Alternative Formulation (AF) Ophthalmic

Phase 3

Bacterial Conjunctivitis

Optifree Replenish

Phase 3

Myopia

Netarsudil/latanoprost ophthalmic

Phase 3

Ocular Hypertension

Travoprost APS 40 micrograms/ml eye drop solution

Phase 3

Open Angle Glaucoma

Travoprost

Phase 3

Glaucoma, Open-Angle

Ocriplasmin

Phase 3

Symptomatic Vitreomacular Adhesion

Moxifloxacin ophthalmic

Phase 3

Bacterial Conjunctivitis

Tobradex ST

Phase 3

Blepharitis

Nepafenac eye drops

Phase 3

Cataracts

Brinzolamide + Timolol eye drops

Phase 3

Open-angle Glaucoma

Travoprost/Timolol BAC-free ophthalmic

Phase 3

Open-Angle Glaucoma

Triamcinolone Acetonide Injectable Suspension

Phase 3

Vitrectomy

Apraclonidine Hydrochloride Ophthalmic Solution

Phase 3

Ocular Redness

Travoprost Ophthalmic

Phase 3

Open-angle Glaucoma

BETOPTIC S (betaxolol HCl)

Phase 3

Glaucoma

quinolone

Phase 3

Bacterial Conjunctivitis

Prednisolone acetate

Phase 3

Non-Proliferative Diabetic Retinopathy

AL-3862+timolol ophthalmic suspension

Phase 3

Glaucoma

Nepafenac ophthalmic suspension (NEVANAC)

Phase 3

Macular Edema

Moxifloxacin Alternative Formulation Ophthalmic

Phase 3

Bacterial Conjunctivitis

Travoprost/Timolol Maleate Fixed Combination solution

Phase 3

Open-angle Glaucoma

Dexamethasone phosphate otic solution

Phase 3

Acute Otitis Externa

Latanoprost ophthalmic solution (XALATAN®)

Phase 3

Open-angle Glaucoma

Olopatadine Hydrochloride Nasal

Phase 3

Allergic Rhinitis

Olopatadine nasal

Phase 3

Perennial Allergic Rhinitis

Travatan

Phase 3

Glaucoma, Open-angle

AL-60371, Otic

Phase 3

Acute Otitis Externa

Timolol maleate ophthalmic

Phase 3

Open-angle Glaucoma

BSS Plus

Phase 3

Cataract

Latanoprost Ophthalmic Solution (XALATAN)

Phase 3

Open-Angle Glaucoma

Rimexolone

Phase 3

Dry Eye

Brimonidine tartrate ophthalmic

Phase 3

Open-Angle Glaucoma

Travoprost + Timolol eye drops, solution (DuoTrav)

Phase 3

Glaucoma

Travoprost PQ ophthalmic

Phase 3

Pediatric Glaucoma

Brinzolamide (AZOPT) eye drops

Phase 3

Open-angle Glaucoma

Brinzolamide/brimonidine tartrate ophthalmic

Phase 3

Open-Angle Glaucoma

Prednisolone acetate ophthalmic

Phase 3

Endogenous Anterior Uveitis

ClearCare

Phase 3

Myopia

Apraclonidine Ophthalmic Solution, Unit Dose Preservative Free

Phase 3

Ocular Hyperemia

Moxifloxacin and Dexamethasone combined

Phase 3

Blepharitis

Artificial tears

Phase 3

Dry Eye Disease

Timolol Gel-forming Solution (TGFS)

Phase 3

Glaucoma

Latanoprost/Timolol

Phase 3

Glaucoma, Open-Angle

Systane Ultra eyedrops

Phase 3

Xerophthalmia

Dorzolamide+timolol ophthalmic solution

Phase 3

Glaucoma

AZOPT (brinzolamide)

Phase 3

Glaucoma

Triesence

Phase 3

Glaucoma

AL-4943A ophthalmic solution

Phase 3

Allergic Conjunctivitis

Ofloxacin otic solution

Phase 3

Acute Otitis Media

Travoprost/Timolol maleate ophthalmic

Phase 3

Glaucoma, Open-angle

Brinzolamide ophthalmic

Phase 3

Open-Angle Glaucoma

Travoprost, Investigational

Phase 3

Open-angle Glaucoma

Next Generation Ophthalmic Irrigating Solution (NGOIS)

Phase 3

Cataract

Difluprednate ophthalmic emulsion

Phase 3

Cataracts

Travoprost/Timolol

Phase 3

Open-angle Glaucoma

Travoprost with and without BAK

Phase 3

Open-angle Glaucoma

Tobramycin/Dexamethasone ophthalmic

Phase 3

Cataract

Tobramycin/Dexamethasone

Phase 3

Ocular Inflammation Associated With Blepharaconjunctivitis

Brinzolamide/Brimonidine fixed combination eye drops

Phase 3

Open-Angle Glaucoma

AR-15512 ophthalmic

Phase 3

Dry Eye Disease

anecortave acetate

Phase 3

Macular Degeneration

Tobradex AF

Phase 3

Cataract

EXE844 Sterile Otic

Phase 3

Otitis Media With Effusion in Children

Travoprost/Timolol Ophthalmic

Phase 3

Open-angle Glaucoma

Sodium Hyaluronate Ophthalmic

Phase 3

Dry Eye Syndrome

Alcon Investigational Agent

Phase 3

Open-Angle Glaucoma

Brimonidine Tartrate Ophthalmic Solution

Phase 3

Open-Angle Glaucoma

Brinzolamide/Timolol fixed combination ophthalmic

Phase 3

Open-Angle Glaucoma

Brinzolamide/brimonidine tartrate fixed combination ophthalmic

Phase 3

Open-Angle Glaucoma

Travoprost ophthalmic solution with SofZia® preservative system (TRAVATAN Z®)

Phase 3

Open-angle Glaucoma

Latanoprost

Phase 3

Glaucoma, Angle-Closure

AR-15512

Phase 3

Dry Eye Disease

FID 123320 Ophthalmic Solution

Phase 3

Ocular Redness

Brolucizumab ophthalmic solution

Phase 3

Neovascular Age-Related Macular Degeneration

Moxidex otic solution

Phase 3

Acute Otitis Media

Nepafenac ophthalmic

Phase 3

Cataract

Anecortave Acetate Sterile

Phase 3

Macular Degeneration

IOP Lowering Medications

Phase 3

Open-Angle Glaucoma

Moxifloxacin otic solution

Phase 3

Acute Otitis Media

BETAXON (levobetaxolol HCl)

Phase 3

Glaucoma

Olopatadine Hydrochloride Ophthalmic

Phase 3

Allergic Conjunctivitis

Travoprost (POLYQUAD-preserved) Eye Drops

Phase 3

Open Angle Glaucoma

LME636 ophthalmic

Phase 2

Acute Anterior Uveitis

AL-3789 Sterile Suspension

Phase 2

Open-angle Glaucoma

PG043 Ophthalmic Solution

Phase 2

Open Angle Glaucoma

Timolol Maleate Ophthalmic Gel Forming

Phase 2

Open-angle Glaucoma

AL-12182 Ophthalmic

Phase 2

Open-angle Glaucoma

AL-54478

Phase 2

Open-angle Glaucoma (OAG)

Hydroxypropyl Guar Galactomannan (HPGG) ophthalmic

Phase 2

Dry Eye

AL-38583 ophthalmic solution

Phase 2

Allergic Conjunctivitis

AL-39324 ophthalmic suspension

Phase 2

Age Related Macular Degeneration

AL-37807

Phase 2

Open-Angle Glaucoma

Brinzolamide/Timolol

Phase 2

Open-angle Glaucoma

Travoprost (Groups A, B and C)

Phase 2

Open-angle Glaucoma (OAG)

CLG561

Phase 2

Geographic Atrophy

Hydroxypropyl Guar Galactomannan

Phase 2

Dry Eye Disease

Travoprost/brinzolamide

Phase 2

Open-angle Glaucoma

Anecortave Acetate Suspension Depot

Phase 2

Eye Diseases

Dose Level A/Brinzolamide ophthalmic

Phase 2

Glaucoma

ESBA1008 solution

Phase 2

Exudative Age-Related Macular Degeneration

ESBA105 ophthalmic solution

Phase 2

Eyes Dry Chronic

Brolucizumab/50 μL

Phase 2

Neovascular Age-Related Macular Degeneration

AR-14034 SR implant lower dose

Phase 2

Neovascular Age-related Macular Degeneration (nAMD)

Dose Level B/Brinzolamide ophthalmic

Phase 2

Glaucoma

AL-37807 Ophthalmic

Phase 2

Open-angle Glaucoma

Dose Level C/Brinzolamide ophthalmic

Phase 2

Glaucoma

Travoprost ophthalmic solution (new formulation)

Phase 2

Ocular Hypertension

LME636 ophthalmic solution

Phase 2

Dry Eye

LHA510 ophthalmic suspension

Phase 2

Exudative Age-Related Macular Degeneration

AL-53817 Ophthalmic

Phase 2

Allergic Conjunctivitis

Travoprost Vehicle

Phase 2

Open-angle Glaucoma (OAG)

Systane COMPLETE Lubricant Eye Drops

Phase 2

Dry Eye Syndromes

AL-38583 ophthalmic

Phase 2

Dry Eye

AR-14034 SR implant higher dose

Phase 2

Neovascular Age-related Macular Degeneration (nAMD)

antioxidants tablets

Phase 2

Central Serous Chorioretinopathy

AR-14034 SR implant

Phase 2

Neovascular Age-related Macular Degeneration (nAMD)

Glaucoma therapy

Phase 2

Open-Angle Glaucoma

Ranibizumab ophthalmic solution

Phase 2

Exudative Age-Related Macular Degeneration

Ranibizumab

Phase 2

Exudative Age-Related Macular Degeneration

Xalatan

Phase 2

Open-Angle Glaucoma

AL-78843 Ophthalmic

Phase 2

Allergic Conjunctivitis

AL-78898A

Phase 2

Exudative Age-Related Macular Degeneration

Combination IOP Lowering Therapy

Phase 2

Glaucoma, Open-angle

AR-17043 Ophthalmic Solution

Phase 2

Open Angle Glaucoma

MGV354 ophthalmic suspension

Phase 2

Ocular Hypertension

Prednisolone acetate ophthalmic suspension (OMNIPRED)

Phase 2

Macular Edema

AL-39256 Ophthalmic

Phase 2

Open-Angle Glaucoma

eye drops (OTC)

1 drug in this indication

Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)

📑
Catalyst DossierPRO
The full research note — thesis, the if-approved scenario, financials & smart money. Compiled by CeliA.
→

Frequently asked questions

What is in Alcon Research's drug pipeline?→

CatalystAlert tracks 127 drug candidates in Alcon Research's (ALC) pipeline across Phase 3, Phase 2. Its lead program is Apraclonidine Ophthalmic Solution, Unit Dose Preservative Free (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.

When is Alcon Research's next FDA catalyst?→

Alcon Research's (ALC) next tracked catalyst is a Phase 3 readout expected January 2027. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.

How do I track ALC biotech catalysts?→

Add ALC to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Alcon Research's live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.

Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply